EV Biologics Statistics
Total Valuation
EV Biologics has a market cap or net worth of $2.02 million. The enterprise value is $3.50 million.
| Market Cap | 2.02M |
| Enterprise Value | 3.50M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
EV Biologics has 7.23 million shares outstanding. The number of shares has increased by 41.52% in one year.
| Shares Outstanding | 7.23M |
| Shares Change (YoY) | +41.52% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 41.37 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 71.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.13
| Current Ratio | 0.13 |
| Quick Ratio | 0.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -307.52% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $172 |
| Profits Per Employee | -$3,500 |
| Employee Count | 284 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.18% in the last 52 weeks. The beta is -1.14, so EV Biologics's price volatility has been lower than the market average.
| Beta (5Y) | -1.14 |
| 52-Week Price Change | -60.18% |
| 50-Day Moving Average | 0.50 |
| 200-Day Moving Average | 0.87 |
| Relative Strength Index (RSI) | 12.93 |
| Average Volume (20 Days) | 1,041 |
Short Selling Information
The latest short interest is 91,374, so 1.26% of the outstanding shares have been sold short.
| Short Interest | 91,374 |
| Short Previous Month | 251,296 |
| Short % of Shares Out | 1.26% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.12 |
Income Statement
In the last 12 months, EV Biologics had revenue of $48,900 and -$993,991 in losses. Loss per share was -$0.12.
| Revenue | 48,900 |
| Gross Profit | 48,900 |
| Operating Income | -687,360 |
| Pretax Income | -993,991 |
| Net Income | -993,991 |
| EBITDA | -687,360 |
| EBIT | n/a |
| Loss Per Share | -$0.12 |
Balance Sheet
The company has $20,648 in cash and $1.50 million in debt, giving a net cash position of -$1.48 million or -$0.20 per share.
| Cash & Cash Equivalents | 20,648 |
| Total Debt | 1.50M |
| Net Cash | -1.48M |
| Net Cash Per Share | -$0.20 |
| Equity (Book Value) | -1.88M |
| Book Value Per Share | -0.26 |
| Working Capital | -1.92M |
Cash Flow
In the last 12 months, operating cash flow was -$3.28 million and capital expenditures -$35,179, giving a free cash flow of -$3.31 million.
| Operating Cash Flow | -3.28M |
| Capital Expenditures | -35,179 |
| Free Cash Flow | -3.31M |
| FCF Per Share | -$0.32 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,405.64% and -2,032.70%.
| Gross Margin | 100.00% |
| Operating Margin | -1,405.64% |
| Pretax Margin | -2,032.70% |
| Profit Margin | -2,032.70% |
| EBITDA Margin | -1,405.64% |
| EBIT Margin | n/a |
| FCF Margin | -6,774.17% |
Dividends & Yields
EV Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.52% |
| Shareholder Yield | -41.52% |
| Earnings Yield | -49.13% |
| FCF Yield | -163.74% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 9, 2017. It was a reverse split with a ratio of 1:5.
| Last Split Date | Nov 9, 2017 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |